Kornimate/medical-research-clean huggingface dataset:
multimedia animations to support therapeutic exercise for rotator cuff shoulder pain

Conditions: Rotator Cuff Impingement Syndrome; Rotator Cuff Tendinitis; Rotator Cuff Related Shoulder Pain

Summary: the goal of this randomized controlled trial is to evaluate the benefits from adding multimedia animations to a paper-based therapeutic exercise program in subjects with rotator cuff related shoulder pain. the main question\[s\] it aims to answer are: * does subjects improve more regarding shoulder disability and pain? * are the subjects more satisfied with the treatment received? * do the subjects adhere more to the exercise program? * do the subjects have greater expectations with the treatment received? participants will perform a therapeutic exercise program within 6 months. researchers will compare the addition of web-app animations to the classical paper-based information.


Eligibility criteria:
inclusion criteria: * presence of rotator cuff related shoulder pain, diagnosed as unilateral shoulder pain, located in the anterior and/or lateral deltoid region, which is reproduced by active elevation and/or lying on ipsilateral side, and with at least one the following orthopaedic tests: neer, hawkins-kennedy and/or empty can. * pain lasting from at least 3-months. * pain intensity at rest, during movement, and sleeping ≥ 3/10 points on a numeric pain rating scale. * to have a mobile phone, tablet or computer with internet connection. * to understand written and spoken spanish language. exclusion criteria: * history of major trauma or surgery on the shoulder, elbow, or cervical spine. * signs of other shoulder pathologies such as instability, frozen shoulder, calcific tendonitis, severe arthrosis, or neuralgic amyotrophy. * presence of full-thickness rotator cuff tears on ultrasound imaging. * signs and/or symptoms of neck-related shoulder pain and/or radiculopathy or radicular pain. * systemic diseases such as cancer, rheumatic disorders, sclerosis multiple, neurological disorders, etc. * severe psychiatric disorders.

Keywords: rotator cuff related shoulder pain therapeutic exercise web-based video
botulinum toxin for the treatment of involuntary movement disorders

Conditions: Movement Disorders

Summary: btx has been used since the 1980s in support of the research mission of ninds. initial studies were focused on expanding the applicability of btx treatment to movement disorders and exploring new indications. we evaluated the efficacy of an alternative serotype, type f. under other protocols, we continue to study the physiology of movement disorders and btx response. the application of btx therapy to movement disorders requires an understanding of btx preparation and handling. the treatment must be tailored to the disorder under treatment and to its expression in the individual patient. users must know the specific techniques of injection, including the use of emg and ultrasound guidance. this protocol allows us to train physicians in all aspects of the use of btx. it also provides us with a cohort of patients, receiving a standard method of treatment and with a stable response to btx injection, for participation in other protocols on movement disorders and on the responses to btx injection.

the efficacy of botulinum toxin (btx) has now been demonstrated for a variety of diseases associated with involuntary muscles spasms or movement. the application of botulinum toxin therapy to movement disorders requires treatment tailored to the individual patient and specific techniques of injection. this protocol 1) allows us to follow the natural history of subjects with movement disorders who receive standard botox injections for treatment of movement disorders and 2) allows us to provide botulinum toxin injections for patients participating in other nih studies.

Eligibility criteria:
* inclusion criteria: 1. patients 2 years and older, will be eligible for participation if they have a disorder that, in the judgment of the treating physician, might be amenable to treatment with btx. 2. applicable disorders include but are not limited to dystonia, hemifacial spasm, blepharospasm, tremor, spasmodic dysphonia, tics, vocal fold tremor, oral lingual dyskinesia, tardive dyskinesia, spasticity, and spasmodic dysphonia. exclusion criteria: 1. women who are planning on becoming pregnant, are pregnant or breastfeeding, for the duration of the condition. 2. subjects who require treatment with an aminoglycoside antibiotic, until treatment is complete. 3. for laryngeal injections, subjects must have a paradoxical vocal fold movement with intermittent stridor due to either gastroesophageal reflux or emotional disorders

Keywords: botulinum toxin btw natural history
nab-paclitaxel plus s-1(as) versus nab-paclitaxel plus gemcitabine(ag) in patients with advanced pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this is a randomized phase ii trial comparing the first-line treatment with nab-paclitaxel plus s-1(as) and nab-paclitaxel plus gemcitabine(ag) in advanced pancreatic ductal adenocarcinoma (pda) with primary tumor nonexcision in chinese patients.

advanced pancreatic ductal adenocarcinoma (pdac) is an aggressive and chemo-resistant disease with extremely low 5-year survival rate. gemcitabine has been the cornerstone of metastatic pdac treatment for more than a decade , although survival benefit was very poor. nab-paclitaxel added to gemcitabine has showed improving survival and overall response rate vs gemcitabine alone in metastatic pdac first-line treatment in the mpact phaseiii study, which represents one of the standards of care in advanced pdac therapy. s-1 is an oral 5-fluorouracil (5-fu) prodrug, and shown to be non-inferior to gemcitabine on os for unresectable pancreatic cancer. meanwhile, adjuvant chemotherapy with s-1 monotherapy was found to significant prolong survival of pancreatic cancer patients when compared with gemcitabine. this study is to explore the efficacy and safety of nab-paclitaxel plus s-1(as) and nab-paclitaxel plus gemcitabine(ag) as first-line treatment in advanced pancreatic ductal adenocarcinoma (pda) with primary tumor nonexcision in chinese patients.

Eligibility criteria:
inclusion criteria: 1. signed informed-consent form. 2. age no less than 18 years. 3. histologically confirmed locally advanced or metastatic pancreatic ductal adenocarcinoma, with recist measurable lesions. 4. eastern cooperative oncology group (ecog) 0-1 with life expectation of no less than 12 weeks. 5. patients must have received no previous chemotherapy or investigational therapy for the treatment of locally advanced or metastatic disease. 6. at least 4 weeks since completion of the last operation except for diagnostic biopsy. 7. at least 4 weeks since completion of radiotherapy to lesions. 8. not suitable for local treatment. 9. adequate liver/bone marrow function. 10. human chorionic gonadotropin (hcg) test negative for female with contraception measure until 3 months after study end. 11. compliant, and can be followed up regularly. exclusion criteria: 1. received chemotherapy or investigational therapy for the treatment of locally advanced or metastatic disease. 2. pregnant or breast-feeding female, or not willing to take contraception measures during study. 3. serious infection requiring antibiotics intervention during recruitment. 4. allergic to study drug. 5. more than grade 1 neuropathy. 6. uncontrolled brain metastasis or mental illness. 7. congestive heart failure, uncontrolled cardiac arrhythmia, etc. 8. other malignancy within 5 years. 9. can't be followed up or obey protocol. 10. ineligible by the discretion of the investigator.

Keywords: advanced pancreatic cancer nanoparticle albumin-bound paclitaxel s-1 gemcitabine
fibrillatory factor in ventricular tachycardia

Conditions: Ventricular Tachycardia

Summary: this study involves recording electrical signals inside the heart during an ablation procedure. it is thought that by studying these electrical signals in detail the investigators may be able to better identify and treat patients at risk of ventricular tachycardia (vt). vt is where the lower chambers (ventricles) of your heart beat fast and this condition can be life-threatening. an ablation procedure is performed in patients who have vt despite the best treatment available with tablets. cardiac ablation involves interrupting the abnormal electrical signals, which cause vt, by applying a type of electrical energy through a catheter. an important part of the ablation procedure is the identification of the exact part of the heart muscle responsible for causing the vt. this typically involves sampling the electrical signals in lots of different areas of the heart, which allows the construction of computer generated 3 dimensional pictures of the structure and the electrical circuits inside the ventricle. recent research has identified a new method to interpret these electrical signals (called fibrillatory factor - ff), which may allow better identification of the area within the ventricle that should be ablated. a standard vt ablation will often involve us controlling the heart-beat by pacing the heart through 1 of the investigators catheters within the heart. the electrical response to pacing at different heart rates can often provide your doctor with information to help the ablation. this study will involve an additional period of pacing at different heart rates, during which the electrical response is measured in different areas around the ventricle. this will allow us to calculate areas of the ventricle, which the investigators new measure ff would predict to be the source of the vt. in the future this may then allow us to better identify patients who are at risk of vt, and to better locate the area that needs to be ablated.


Eligibility criteria:
inclusion criteria: * age 18 or above, and capable of giving informed consent * scheduled for a clinically indicated cardiac ablation for the treatment of ventricular tachycardia exclusion criteria: * moderate or severe aortic stenosis or mitral stenosis * active infection * presence of thrombus, cardiac tumour, interatrial baffle patch (a specific form of congenital cardiac surgery) or prior septal occluder device * subjects who cannot be anticoagulated of infused with heparinized saline * a history of heparin induced thrombocytopenia * pregnant or actively breast feeding

Keywords: ventricular tachycardia
effects of oral nutritional supplementation in children at risk of undernutrition

Conditions: Undernutrition

Summary: this prospective, randomized, controlled study will evaluate the effects of oral nutritional supplementation plus dietary counseling versus dietary counseling alone in children at nutritional risk.


Eligibility criteria:
inclusion criteria: * children 24-60 months old * undernourished or at risk of undernutrition according to the who growth standards. * child's parent(s)/legal guardian (lg) is willing to abstain from giving additional non-study ons other than the study product during the study intervention period. * child's parent(s)/lg is able and willing to follow study procedures and record data in parent diary and complete any forms or assessments needed throughout the study. * child's parent(s)/lg is not planning to relocate during the study period. * child's parent(s)/lg has voluntarily signed and dated an informed consent form (icf), approved by an independent ethics committee/institutional review board (iec/irb) or other applicable privacy regulation authorization prior to any participation in the study. exclusion criteria: * participant participates in another study that has not been approved as a concomitant study. * child is known to have galactosemia, be allergic or intolerant to any ingredient found in the study product. * child is currently drinking an abbott product(s). * child had a history of preterm delivery, defined as a birth before 37 completed weeks of gestation as reported by parent(s)/lg. * child had birth weight \ 4000 g. * child whose either parent has bmi ≥ 27.5 kg/m2 * child has continuous oral nutrition supplement (ons) usage for at least 15 days in the past 1 month prior to screening. the standard ons formula usually has an energy density of at least 1 kcal/ml, containing protein, carbohydrate and/or fat, as well as a wide range of micronutrients to supplement or use as the sole source of nutrition. * child has current acute or chronic infections including but not restricted to respiratory infections, diarrhea, acute and chronic hepatitis b or c, hiv infection or tuberculosis. * child has been diagnosed with the following according to medical records or report by parent(s)/lg or the clinician's judgment: 1. severe gastrointestinal disorders such as celiac disease, short bowel syndrome, pancreatic insufficiency, or cystic (exception: intestinal parasites infection) 2. neoplastic, renal, hepatic or cardiovascular, hormonal or metabolic disorders, congenital disease or genetic disorders such as atrial or ventricular wall defects, down's syndrome, or thalassemia 3. infantile anorexia nervosa, developmental disability, including physical disorders such as cerebral palsy, or developmental delay 4. disorders of hemoglobin structure, function or synthesis 5. clinically significant nutritional deficiency requiring specific treatment with another nutritional supplement (other than the study product) as diagnosed by the investigator. 6. any other clinically significant medical condition, which in the investigator's opinion, makes him or her unsuitable for inclusion in the study.
co2 monitoring at preterm delivery-observational study

Conditions: Resuscitation

Summary: co2 data, serving as a proxy marker for tidal volume, might enable titration of tidal volume/pressure thereby providing optimal ventilation during neonatal resuscitation. currently there is insufficient data on co2 levels for preterm babies requiring resuscitation. this study involves monitoring of co2 during preterm stabilisation.

measurement of exhaled co2 in the delivery room is feasible, but clinical benefits of during neonatal transition have not been studied. volume ventilation in the neonatal unit has been shown to improve outcomes such bpd or death. despite the proven benefits of volume ventilation in the neonatal unit volume guided resuscitation at birth remains an unproven and under-studied technique. co2 data, serving as a proxy marker for tidal volume, might enable titration of tidal volume/pressure thereby providing optimal ventilation during neonatal resuscitation. currently there is insufficient data on co2 levels for preterm babies requiring resuscitation. this data would help in finding out optimal resuscitation strategies (pressures/volume, frequency of breaths) rather than providing the same for all infants throughout the process of resuscitation and would help us in better interpretation co2 levels in the future resuscitation. investigators aim to study the impact of various clinical (gestation, birth weight, need for intubation/bag-mask ventilation) and resuscitative factors (use of inflation pressures, ventilation pressures, frequency of breaths, face mask ventilation, intubation) on co2 during preterm stabilisation.

Eligibility criteria:
inclusion criteria: 1. all preterm infants ≤ 32 weeks born at the study centres. 2. needing resuscitative measures at the time of birth either in the form of face mask ventilation or intubation. exclusion criteria: 1. preterm infants below the threshold of viability as determined by the study team. 2. major congenital or chromosomal abnormality (including congenital heart disease, diaphragmatic hernia, congenital pulmonary airway malformations). 3. severe oligohydramnios (amniotic fluid index \<5 or deep vertical pool≤2).

Keywords: carbon dioxide monitoring preterm resuscitation
glucocorticoids combined with concurrent chemoradiotherapy for unresectable thymoma

Conditions: Thymoma

Summary: this study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.

this study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma. patients will receive hypofractionated radiotherapy with concurrent chemotherapy. methylprednisolone will be administered daily during radiotherapy at a dose of 2 mg/kg.

Eligibility criteria:
inclusion criteria: * histologically confirmed type ab or b1-3 thymoma. * measurable disease: patients must have measurable disease as defined by recist (response evaluation criteria in solid tumors). * unresectable or recurrent thymoma, with the tumor confined to the chest and neck area. * between the ages of 18 and 70 years, regardless of sex. * eastern cooperative oncology group performance status of 0 or 1. * no prior chest radiation. * adequate organ functions. * written informed consent obtained. exclusion criteria: * contraindications to methylprednisolone. * history of or concurrent malignancy. * active infection, myocardial infarction within the last 6 months or symptomatic heart disease. * pregnant or lactating women. * bleeding disorders. * recent participation in other clinical trials. * drug abuse or severe alcoholism. * uncontrolled seizures or mental disorders. * severe allergies or specific sensitivities.

Keywords: thymoma concurrent chemoradiotherapy methylprednisolone
a pilot study evaluating oral triamcinalone in patients with androgen independent prostate cancer

Conditions: Prostate Cancer

Summary: the primary purpose of this study is to evaluate the ability of oral triamcinalone given twice a day to patients with androgen independent prostate cancer to produce a sustained biochemical response. secondary goals are to describe the safety and tolerability at this dose and schedule, to determine the time to sustained biochemical response, to determine the duration of biochemical response, to determine the time to disease progression.


Eligibility criteria:
inclusion criteria: * 18 years of age and older * histologically documented adenocarcinoma of prostate * currently receiving lhrh agonists with castrate levels of testosterone or who have had an orchiectomy * must have had a rise in psa despite anti androgen withdrawal * exhibit 2 consecutive rise in psa after the last hormonal manipulation * minimum psa of greater than 5 kps greater than 80% * normal cortisol level at entry * life expectancy greater than 6 months * provide written consent pursuant to regulatory requirements prior to initiation of study procedure exclusion criteria: * younger than 18 years * patients without prostate cancer

Keywords: oral triamcinalone prostate cancer
impact of the coronavirus disease 2019 (covid-19) on sperm parameters

Conditions: Covid19; Infertility, Male

Summary: this study aims to better understand the effects of the severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection, virus that causes the coronavirus disease 2019 (covid-19), on male fertility.

after being informed about the study and potential risks, all patients giving written informed consent will produce a sperm sample by masturbation. patients will also complete a questionnaire relating to their state of health. six month following the first sperm sample, patients will produce another sperm sample by masturbation. these sperm parameters will be compared with the ones from a sperm analysis performed less than 2 years before the sars-cov-2 infection.

Eligibility criteria:
inclusion criteria: * all men aged 18 to 45 having a sperm analysis done at the fertilys fertility center in the last 2 years who have not contracted covid-19, agreeing to participate in the study and having signed the consent form to participate in the study. * all men aged 18 to 45 having a sperm analysis done at the fertilys fertility center in the last 2 years) who have contracted covid-19 within the last 6 months, agreeing to participating in the study and having signed the consent form to participate in the study. * all men aged 18 to 45 years with a sperm concentration ≥ 15 million/ml, progressive motility ≥ 20% and a percentage of normal forms ≥ 2%. exclusion criteria: * men aged under 18 and over 45. * men who cannot produce a sperm sample by antegrade ejaculation. * men whose sperm concentration is \<15 million/ml, progressive motility \<20% and a percentage of normal forms \<2%, determined following the production of a "reference" sperm sample, carried out before march 2020, i.e. before the covid-19 pandemic.
danish osteoporosis prevention study

Conditions: Osteoporosis

Summary: hypothesis: use of hormone replacement therapy (hrt) decreases the incidence of fractures in early postmenopausal women. the project was initiated in 1990, and the inclusion ended in 1993. a total of 2,016 early postmenopausal women were divided into two groups: the first group accepted randomisation to hrt or not, and the second group was allowed to choose hrt or not. the study was not blinded. main measurements were fracture risk over 20 years, changes in bone mineral density over 20 years, and side effects, mainly breast cancer.

aim: to study the ability of hormone replacement early after menopause on risk of fractures and changes in bone mineral density, and side effects. the project was designed as a comprehensive cohort trial. one group accepted randomisation, and was randomised to hormone replacement therapy (hrt) or not (no placebo used). 502 were randomised to hrt, and 504 were randomised to no hrt) one group was allowed to choose hrt or not. a total of 221 chose hrt, and 789 chose no hrt. first line hrt was oral sequential oestradiol/norethisterone in women with intact uterus and oral continuous oestradiol in hysterectomised women. the study was initiated in 1990, and inclusion ended in 1993.

Eligibility criteria:
inclusion criteria: * women aged 45-58 years with an intact uterus * three to 24 month past last menstrual bleeding * hysterectomised women aged 45-52 years and having elevated fsh exclusion criteria: * metaboliv bone disease including osteoporosis defined as non-traumatic vertebral fractures on x-ray * current estrogen use or estrogen use within the past three month * current or past treatment with glucocorticoids for more than 6 month * current or past malignancy * newly diagnosed or uncontrolled chronic disease * alcohol or drug addiction

Keywords: fracture osteoporosis bone mineral density hormone replacement therapy estrogen breast cancer
reliability of chinese version of verbal learning test and selective reminding test

Conditions: Mild Cognitive Impairment; Test-retest Reliability

Summary: mild cognitive impairment (mci) is distinguished from healthy aging by cognitive difficulties that are greater than expected for one's age and education. amnestic mild cognitive impairment (amci) is a major sub-type of mci with noticeable impairments in memory. approximately 12% of amci will progress to ad per year. there are two test to evaluate the effects on memory, but both without chinese version. this study is to know the test-retest reliability of the chinese version of the verbal learning test and selective reminding test among people with mild cognitive impairment.


Eligibility criteria:
inclusion criteria: 1. age≥50 years 2. complained of memory impairment 3. chinese version verbal learning test 10-minute delays ≤ 6 words 4. mmse score≥24 and cdr score=0.5 5. activities of daily living are intact 6. dsm-iv criteria for the diagnosis of dementia is not met exclusion criteria: 1. any significant neurologic disease other than suspected incipient alzheimer's disease 2. psychotic features, contraindication of exercise... which could lead to difficulty complying with the protocol